Tactile Systems Technology Inc

Análisis de la acción Tactile Systems Technology Inc (TCMD)

$23.640

+0.099 (+0.42%)Al cierre

Loading chart…
Máximo
23.840
Apertura
23.560
Precio medio ponderado por volumen
23.65
Volumen
130.81K
Capitalización
274.93M
Mínimo
23.480
Importe
3.09M
EV/EBITDA, TTM
12.47

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.

Análisis de IA of Tactile Systems Technology Inc (TCMD)

Comprar

Tactile Systems Technology Inc is a good buy right now due to its current price of $22.52, which is significantly lower than the analyst price target of $36, indicating a potential upside of 60%. Additionally, the company has shown strong revenue growth with Q2 2026 revenue at $85.7 million, a 9% year-over-year increase, and a gross margin of 76.3%. The main risk is the recent decline in stock price, with a 1-year change of +54.14% and a year-to-date change of -17.81%, indicating volatility.

Recomendaciones de analistas (6)

+33.97% de potencial alcista
Comprar
6 Comprar
0 Mantener
0 Vender
Actual: 23.64
Mínimo
28.00
Promedio
31.67
Máximo
35.00

BTIG

2026-10-12

Precio objetivo

$35

Comprar

B. Riley

2026-05-07

Precio objetivo

$36

Comprar

BTIG

2026-05-05

Precio objetivo

$40

Comprar

BTIG

2026-02-18

Precio objetivo

$38

Comprar

B. Riley

2026-02-18

Precio objetivo

$32

Neutral

Métricas de valoración

El PER previsto actual de Tactile Systems Technology Inc (TCMD) es 19.12, frente a su media de 5 años de 75.74.

PER previsto

Valor razonable
Media 5A P/E
75.74
P/E actual
19.12
Sobrevalorada
435.21
Infravalorada
-283.73

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-7.58
EV/EBITDA actual
12.47
Sobrevalorada
75.67
Infravalorada
-90.83

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.22
P/S actual
1.34
Sobrevalorada
1.64
Infravalorada
0.81

Escenarios de precio de Alphio AI para TCMD

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%TCMD

$12.55

Precio del escenario

B

Base

Base · 50%TCMD

$12.06

Precio del escenario

B

Bajista

Bajista · 25%TCMD

$10.94

Precio del escenario

Ballenas con TCMD en cartera

F

First Light Asset Management, LLC

+ Con en carteraTCMD

-9.40%

Rentabilidad a 3 meses

Cronología de eventos

2026-08-10 (ET)

16:30:00

Tactile Medical Q2 Revenue $85.7M Beats Expectations

2026-05-04 (ET)

16:30:00

Company Updates 2026 Revenue Outlook to $368 Million

16:30:00

Tactile Medical Q1 Revenue $75.27M, Exceeds Expectations

2026-03-09 (ET)

08:30:00

Tactile Systems Appoints Andrea Pearson to Board of Directors

2026-02-17 (ET)

17:00:00

Tactile Systems Acquires LymphaTech for $6.8M

Noticias

Preguntas frecuentes sobre TCMD, respondidas por Alphio AI

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tactile Systems Technology Inc is a good buy right now due to its current price of $22.52, which is significantly lower than the analyst price target of $36, indicating a potential upside of 60%. Additionally, the company has shown strong revenue growth with Q2 2026 revenue at $85.7 million, a 9% year-over-year increase, and a gross margin of 76.3%. The main risk is the recent decline in stock price, with a 1-year change of +54.14% and a year-to-date change of -17.81%, indicating volatility.

6 analysts cover TCMD: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.67.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar